Compton Wealth Advisory Group LLC Cuts Stake in Johnson & Johnson (NYSE:JNJ)

Compton Wealth Advisory Group LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 8.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,135 shares of the company’s stock after selling 707 shares during the period. Compton Wealth Advisory Group LLC’s holdings in Johnson & Johnson were worth $1,176,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Hardin Capital Partners LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $778,000. SYM FINANCIAL Corp increased its holdings in Johnson & Johnson by 45.3% during the 2nd quarter. SYM FINANCIAL Corp now owns 6,815 shares of the company’s stock valued at $996,000 after acquiring an additional 2,126 shares in the last quarter. Mcintyre Freedman & Flynn Investment Advisers Inc. increased its holdings in Johnson & Johnson by 0.8% during the 2nd quarter. Mcintyre Freedman & Flynn Investment Advisers Inc. now owns 12,291 shares of the company’s stock valued at $1,796,000 after acquiring an additional 99 shares in the last quarter. Westover Capital Advisors LLC boosted its stake in shares of Johnson & Johnson by 90.2% during the 2nd quarter. Westover Capital Advisors LLC now owns 5,983 shares of the company’s stock worth $874,000 after purchasing an additional 2,837 shares during the last quarter. Finally, Schiavi & Co LLC boosted its position in shares of Johnson & Johnson by 11.4% in the second quarter. Schiavi & Co LLC now owns 3,136 shares of the company’s stock worth $458,000 after acquiring an additional 320 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock traded up $0.60 during trading on Monday, hitting $142.66. The company had a trading volume of 3,038,824 shares, compared to its average volume of 7,282,141. The firm has a market capitalization of $343.47 billion, a price-to-earnings ratio of 20.65, a P/E/G ratio of 2.52 and a beta of 0.51. The business has a 50 day moving average of $149.67 and a 200 day moving average of $156.11. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the previous year, the business earned $2.66 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.2% compared to the same quarter last year. As a group, research analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.48%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Analysts Set New Price Targets

Several research firms recently issued reports on JNJ. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 7th. Citigroup dropped their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Bank of America restated a “neutral” rating and issued a $166.00 price target on shares of Johnson & Johnson in a research note on Tuesday, December 10th. Finally, Guggenheim boosted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $174.71.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.